Accessibility Menu

Stratec Se(FRA) SBS

Market Cap€273.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)+547%
5 Year-82%
1 Year-7%
1 Month+30%
€24.35
+8.22%
+1.85Today
Stratec Se last closing stock price
MetricPriceDate
Last closeEUR 25.352026-08-31
Stratec Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.42%EUR 22.352026-08-24
1 month+29.87%EUR 19.522026-07-31
3 month+51.07%EUR 16.782026-06-02
Year to date+12.92%EUR 22.452025-12-30
1 year-6.8%EUR 27.202025-08-29
3 year-48.63%EUR 49.352023-09-01
5 year-82.15%EUR 142.002021-09-01
Since inception+547.09%EUR 3.481998-10-05

Stratec Se Financials at a Glance

Market Cap

€273.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€244.81

Net Income (TTM)

-€0.40

EPS (TTM)

-€0.03

P/E Ratio

-692.31

Dividend

€0.60

Beta (Volatility)

0.05 (Low)

Price

€24.35

Volume

100

Open

€23.65

Previous Close

€24.35

Daily Range

€23.65 - €24.35

52-Week Range

€16.38 - €32.20

Estimated Earnings Date

N/A

SBS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stratec Se

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. It operates through the following segments: Instrumentation, Diatron, Smart Consumables, and Other Activities. The Instrumentation segment consults, designs, develops and produces fully automated solutions for its partners in the fields of diagnostics including blood banking. The Diatron segment comprises the business with systems, system components, consumables and tests in the low throughput hematology and clinical chemistry segment. The Smart Consumables segment includes the business with developing and manufacturing smart consumables in the fields of diagnostics, life sciences, and medical technology. The Other Activities segment covers the development of work flow software for networking several analyzer systems and the development and sale of scientific materials and technologies. The company was founded by Hermann Leistner in 1979 and is headquartered in Birkenfeld, Germany.

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,383

CEO

Marcus Wolfinger

Website

www.stratec.com

SBS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-0.14%

Dividend Yield

2.67%

Payout Ratio

N/A

Stock Overview

Market Cap

€273.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.16M

Volume

100

Avg. Volume

53.182

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Stratec Se Performance Analysis

Stratec Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 274,625,000-4.4%
20232023-12-31EUR 270,414,000-1.5%
20242024-12-31EUR 257,624,000-4.7%
20252025-12-31EUR 250,863,000-2.6%
Stratec Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.40-26.8%
20232023-12-31EUR 1.26-47.3%
20242024-12-31EUR 1.324.2%
20252025-12-31EUR -0.02N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€59.11

+0.7%

Gross Profit

€15.24

+0.5%

Gross Margin

25.78%

+0.7%

Market Cap

€273.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.15

+0.6%

Employees

1,383

+1.0%

Net Income

€4.16

+0.4%

EBITDA

€8.52

+0.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€134.75

-24.2%

Total Debt

€115.72

+0.9%

Accounts Receivable

€55.03

+1.3%

Inventory

€114.61

+0.9%

Long Term Debt

€100.16

+1.2%

Short Term Debt

€15.56

+0.3%

Return on Assets

3.41%

N/A

Return on Invested Capital

6.62%

+0.8%

Free Cash Flow

€7.04

+1.1%

Operating Cash Flow

€8.22

+1.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About SBS

What is the current price of Stratec Se?

Stratec Se is trading at €24.35 per share.

What is the 52-week range for Stratec Se?

Over the past 52 weeks, Stratec Se has traded between €16.38 and €32.20.

How much debt does Stratec Se have?

As of the most recent reporting period, Stratec Se reported total debt of €115.72M.

How much cash does Stratec Se have on hand?

Stratec Se reported €19.03M in cash and cash equivalents in its most recent financial results.

What is Stratec Se’s dividend yield?

Stratec Se currently has a dividend yield of 2.67%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services